Close Menu

Big Deal?

After receiving a promotional email from Elsevier, DrugMonkey considers what constitutes a noteworthy change in a journal's impact factor at his blog this week. The email, he says, advertises that one of the publisher's many titles saw a 0.336 boost in its impact factor from 2010 to 2011.

"Is this a significant difference? Who gives a hoot if the IF [impact factor] goes up by 0.336?" DrugMonkey asks. "Is this in any way meaningful?"

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.